Sugi Predict

Sugi Predict / Compounds / SCHEMBL21996839

SCHEMBL21996839

SCHEMBL21996839

Cn1c(=O)n(C2CCC(=O)NC2=O)c2cccc(C#CCCC3CCN(C(=O)OC(C)(C)C)CC3)c21

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 16/20 0.44
▸ CRBN Q96SW2 16/20 0.44
▸ IRAK4 Q9NWZ3 1/20 0.37
▸ PRKCG P05129 1/20 0.36
▸ PRKCB P05771 1/20 0.36
▸ PRKCA P17252 1/20 0.36
▸ PRKCH P24723 1/20 0.36
▸ PRKCE Q02156 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21996965 0.93 DDB1 (0.45) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL21069794 0.90 DDB1 (0.42) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL31553900 0.90 DDB1 (0.42) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL30893229 0.89 IRAK4 (0.44) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL30893291 0.89 IRAK4 (0.44) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL21069281 0.89 IRAK4 (0.44) DDB1CRBNIRAK4PRKCGPRKCB
SCHEMBL23832603 0.89 DDB1 (0.45) DDB1CRBNIRAK4
SCHEMBL31003897 0.89 DDB1 (0.41) DDB1CRBNIRAK4
SCHEMBL26849416 0.89 DDB1 (0.41) DDB1CRBNIRAK4
SCHEMBL26634853 0.88 DDB1 (0.40) DDB1CRBNIRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20240293423-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-09-05 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
EP-4225303-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-08-16 — — EP disclosed
CN-116490069-A STAT degradation agent and application thereof 凯麦拉医疗公司 2023-07-25 — — CN disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-13 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
WO-2022077010-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTIC, INC. (US) 2022-04-14 — — WO disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-20220324854-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 DDB1 1267/4885CRBN 187/4885IRAK4 4/4885
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 DDB1 206/4885CRBN 302/4885IRAK4 2913/4885
US-20240293423-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 DDB1 3993/4885CRBN 171/4885IRAK4 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.